Sydney, NSW – May 2, 2024 – BlinkLab Limited (ASX: BB1), an innovative digital healthcare company renowned for its smartphone-based AI diagnostic tools for autism, has proudly announced a new partnership with the Turning Pointe Autism Foundation, based in Naperville, Illinois, to initiate a clinical study focused on enhancing autism diagnostics in children.
This strategic collaboration will utilize BlinkLab's cutting-edge technology to conduct a study involving 200 children—100 previously diagnosed with autism and 100 without. This endeavor is aimed at refining AI and machine learning algorithms in preparation for a larger, FDA registration study scheduled for the latter half of 2024.
Henk-Jan Boele, CEO of BlinkLab commented: “Our partnership with Turning Pointe is more than just collaboration. It is a major step toward fulfilling our mission to make well-established neurobehavioral testing clinically accessible and efficient. Turning Pointe’s dedication to quality education and support aligns perfectly with our goal of leveraging cutting-edge technology to better understand and assist individuals with autism. We are very excited about the possibilities that this collaboration offers for the advancement of autism diagnosis and care.”
Brian Leedman, Chairman of BlinkLab commented: “I am excited to see that our first substantive news following our listing a few weeks ago is a collaboration with this prestigious group in the field of autism research in children. I anticipate many more important announcements such as these as we get closer to the commencement of our FDA registration study later this year”.
About the Study
The study will utilise BlinkLab’s innovative smartphone platform to conduct neurobehavioral testing, including a range of neurometric assessments. This method allows for the precise measurement of various responses and is designed to be non-invasive and child-friendly. The study has been approved by the institutional review board of Princeton University and will adhere to all pertinent guidelines and regulations.
About us:
BlinkLab, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. BlinkLab’s most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge the most advanced technological innovations with groundbreaking scientific research.
Contact details:
Jane Morgan